Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.

epoetin-alpha users without any prescription within the previous 6 months) were treated with biosimilars of epoetin-alpha, with an increasing trend as compared with the previous years (+54.6%). 27 These data were retrieved by the Nationwide OsMed Health-DB Database and have been validated by AIFA to describe drug consumption nationwide. 28 International evidence-based guidelines for the use of ESAs in cancer patients are currently being updated. 5 , 29 , 30 As in other surveys, 31 , 32 ~10% of all enrolled patients received an ESA for off-label indications.

also in 63,971 other papers